Shenzhen Beike Biotechnology Co., Ltd. is a high-tech enterprise specializing in the clinical transformation and technical services of biotherapeutic technology in strategic emerging industries, and its immunotherapy technology and products are well-known in the industry
Founded in July 2005, Shenzhen Beike Biotechnology Co., Ltd. (hereinafter referred to as Beike Biotech) is an early high-tech enterprise specializing in the clinical transformation and technical services of biotherapeutic technology in strategic emerging industries in China. The company has more than 400 employees, of which more than 35% are technical R&D personnel, and has a professional technical R&D team led by a number of experts with outstanding achievements in the field of cells and scholars at home and abroad.
Multiple Subsidiaries:Jiangsu Beike, Shanghai Beike, Anhui Beike, Liaoning Beike, Henan Beike, Guizhou Beike, Jiangxi Beike, Hebei Beike, Beike International (Hong Kong), Beike International (India), etc.
Global Clinical Research Technical Support Network:Beike Biotechnology has carried out cell technology-related cooperation with more than 400 scientific research and medical institutions at home and abroad, and has provided individualized cell preparation technology services for cell therapy for more than 80,000 patients with refractory diseases, including patients from more than 70 countries such as the United States, Canada, the United Kingdom, and Japan, and the remarkable effect has been highly recognized by the international academic community.
Advanced Immune Cell Therapy Technologies:Through strategic licensing, mergers and acquisitions and independent research and development, Beike occupies an important strategic position in the field of immunotherapy. Beike has a variety of internationally advanced immunotherapy technologies and products. ALT803 is considered by the NCI to be a promising interleukin drug for curing cancer. Compared with the current conventional CAR-T, TCR-T and bispecific antibodies, bispecific antibodies, MCAR-T, MCAR-NK cell therapy developed by the main histocompatibility complex antigen recognition receptor R&D platform has more significant therapeutic advantages in diseases such as hematologic malignancies, solid tumors and viral infections.
National Network of Integrated Cell Banks and Regional Cell Preparation Centers:By "laying" a "cell therapy highway network" that can not only meet the timeliness of clinical needs, but also take into account the scale of production, it provides an innovative public technology platform and infrastructure for the clinical transformation of cell therapy technology. It has been built and ordered in Shenzhen, Jiangsu, Guizhou, Jiangxi, Guangxi and XinjiangThe remarkable achievements provide an innovative way for the development model of China's cell therapy industry.
